

Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell

PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Vice Chairman and CEO Robert J. Coury will preside over the NASDAQ Stock Market opening on Friday, Feb. 20 from 9:15 to 9:30 a.m. ET. Coury will ring the opening bell to celebrate the company's switch from The New York Stock Exchange (NYSE) to NASDAQ.

Mylan's common stock began trading on NASDAQ Dec. 29, 2008. The company is listed on the NASDAQ Global Select Market, and its common stock continues to trade under the "MYL" ticker symbol. Mylan's mandatory convertible preferred stock and 1.25% convertible notes also moved to NASDAQ with the ticker symbols "MYLNP" and "MYLNG," respectively.

Feed Information - The Opening Bell is available from 9:20 to 9:35 a.m. on Galaxy 19 C/15, downlink frequency 4000 vertical. The feed can also be found on Ascent fiber 1623. Technical questions should be directed to Jolene Libretto at 646-441-5220.

Radio Feed - An audio transmission of the Opening Bell is also available from 9:20 to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.

Webcast - A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite about.stm.

Photos - To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdag.com/reference/marketsite_events.stm and click on the market open of your choice.

About Mylan

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

```
SOURCE Mylan Inc.

-0- 02/19/2009

/CONTACT: Michael Laffin of Mylan Inc., +1-724-514-1968, or NASDAQ,
Jolene Libretto, +1-646-441-5220/
/Web Site: http://www.mylan.com/
(MYL MYLNG MYLNP)

CO: Mylan Inc.

ST: Pennsylvania
IN: MTC HEA
SU: CCA

PR
-- NE72904 --
8004 02/19/2009 10:00 EST http://www.prnewswire.com
```